Related Experiment Video
Updated: Mar 6, 2026
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Analysis of treatment outcome variations in infantile epileptic spasms syndrome
Xue Gong1,2, Jing Gan1,3, Xiaoqian Wang1
1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Insights
Infantile epileptic spasms syndrome (IESS) treatment outcomes depend on etiology. Genetic causes lead to poorer responses to therapies like ACTH, but combination treatments may help. Understanding these factors optimizes clinical practice for IESS.
Area of Science:
- Pediatric Neurology
- Clinical Genetics
- Epileptology
Background:
- Infantile epileptic spasms syndrome (IESS) presents a significant challenge in pediatric neurology.
- Identifying key factors influencing IESS outcomes is crucial for refining treatment strategies.
- Understanding the interrelationships between etiology and treatment response is vital for optimizing clinical practice.
Purpose of the Study:
- To investigate the primary factors affecting outcomes in children diagnosed with IESS.
- To analyze the interrelationships between genetic and non-genetic etiologies and treatment efficacy.
- To provide evidence-based insights for improving clinical management of IESS.
Main Methods:
- Retrospective, single-center study of 128 children with IESS (April 2019-April 2024).
- Evaluation of genetic and non-genetic etiological subgroups (structural vs. unknown causes).
- Comparison of genetic testing results, correlation, and logistic regression analyses for treatment efficacy and risk factors.
Main Results:
- Gene-positive IESS cases showed earlier onset, hypotonia, and developmental regression.
- Structural abnormalities in gene-negative cases were associated with more frequent EEG hypsarrhythmia.
- Gene-positive group had poorer responses to ACTH and vigabatrin; combination therapy showed promise. Non-ACTH treatment yielded better EEG improvement (p=0.028).
- Therapeutic response rates were 75% (gene-positive) and 100% (gene-negative). Frequent seizures and developmental regression were risk factors for poor response in gene-negative cases.
Conclusions:
- Prognosis of IESS is strongly linked to etiology, with genetic factors correlating with diminished response to standard therapies.
- Combination therapy with ACTH and vigabatrin may enhance outcomes in select IESS patients.
- ACTH treatment may not significantly impact long-term EEG outcomes in IESS, suggesting a need for etiology-guided therapeutic approaches.
Background:
To explore the key factors influencing outcomes in children with infantile epileptic spasms syndrome (IESS) and to elucidate their interrelationships to provide insights for optimizing clinical practice.
Methods:
This is a retrospective, single-center design study, included children diagnosed with IESS at West China Second Hospital of Sichuan University from April 2019 to April 2024. Descriptive analyses were performed to evaluate genetic and non-genetic etiological subgroups, categorized as structural and unknown causes. Genetic testing results were compared across groups. Pearson correlation and logistic regression analyses were employed to examine differences in treatment efficacy and identify associated risk factors.
Results:
In this study, 128 children diagnosed with IESS were enrolled and evenly divided into gene-positive and gene-negative groups. The gene-positive group exhibited earlier seizure onset, with a higher prevalence of hypotonia and developmental regression compared to the gene-negative group. Within the gene-negative group, children were further categorized into structural abnormality and unknown causes subgroups, among which EEG hypsarrhythmia was more frequently observed in the structural abnormality subgroup. The gene-positive group showed significantly poorer responses to ACTH, vigabatrin, and other ASMs. ACTH combined with vigabatrin therapy improved outcomes in some of the children. The non-ACTH treatment group demonstrated superior EEG improvement outcomes when compared with the ACTH-treated group (p = 0.028). The overall therapeutic response rate was satisfactory, with 75% in the gene-positive group and 100% in the gene-negative group. In the gene-negative group, frequent seizures and developmental regression emerged as significant risk factors for poor treatment response.
Conclusion:
The prognosis for IESS remains challenging, with treatment responses closely tied to etiology. Children with genetic etiologies demonstrate poorer responses to ACTH and other ASMs. However, ACTH combination with vigabatrin may improve treatment outcomes in some cases. Our findings suggest that ACTH treatment may not exert a substantial influence on long-term EEG outcomes in children with IESS.
Related Concept Videos
01:29Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...